SCHEMBL4445918

SCHEMBL4445918

O=Cc1ccc(-c2ccc(O)cc2)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH5A1 P51649 1/20 0.84
ABAT P80404 1/20 0.84
ESR1 P03372 2/20 0.58
ESR2 Q92731 1/20 0.58
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 2/20 0.50
MAPT P10636 1/20 0.50
HDAC3 O15379 1/20 0.50
HDAC4 P56524 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC10 Q969S8 1/20 0.50
HDAC11 Q96DB2 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
HDAC9 Q9UKV0 1/20 0.50
HDAC5 Q9UQL6 1/20 0.50
MMP3 P08254 1/20 0.48
BCL2L1 Q07817 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21908191 1.00 ALDH5A1 (0.84) ALDH5A1ABATESR1ESR2KDM4E
4-Hydroxybenzaldehyde SCHEMBL37193 0.92
4-Hydroxybenzaldehyde SCHEMBL19328157 0.92 ALDH5A1 (1.00) ALDH5A1ABATESR1ESR2KDM4E
4-Hydroxybenzaldehyde SCHEMBL30290836 0.89 ALDH5A1 (0.94) ALDH5A1ABATESR1ESR2KDM4E
4-Hydroxybenzaldehyde SCHEMBL29153364 0.89 ALDH5A1 (0.94) ALDH5A1ABATESR1ESR2KDM4E
4-Hydroxybenzaldehyde SCHEMBL28981620 0.89 ALDH5A1 (0.94) ALDH5A1ABATESR1ESR2KDM4E
4-Hydroxybenzaldehyde SCHEMBL2187647 0.89 ALDH5A1 (0.94) ALDH5A1ABATESR1ESR2KDM4E
4-Hydroxybenzaldehyde SCHEMBL5161739 0.89 ALDH5A1 (0.94) ALDH5A1ABATESR1ESR2KDM4E
4-Hydroxybenzaldehyde SCHEMBL28498005 0.89 ALDH5A1 (0.94) ALDH5A1ABATESR1ESR2KDM4E
4-Hydroxybenzaldehyde SCHEMBL29889847 0.89 ALDH5A1 (0.94) ALDH5A1ABATESR1ESR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265146-B2 Integrin receptor inhibitors GENENTECH, INC. (US) 2007-09-04 US claimed
EP-1620392-B1 HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS WYETH CORP (US) 2007-06-27 EP claimed
US-20050187284-A1 Integrin receptor inhibitors GENENTECH, INC. (US) 2005-08-25 US claimed
EP-1330430-A2 INTEGRIN RECEPTOR INHIBITORS GENENTECH, INC. (US) 2003-07-30 EP claimed
US-20020035104-A1 Integrin receptor inhibitors GENENTECH, INC. 2002-03-21 US claimed
WO-2002016313-A2 INTEGRIN RECEPTOR INHIBITORS GENENTECH, INC. (US) 2002-02-28 WO claimed
US-6177500-B1 CONTAINING A P-OXYBENZOYL UNIT (A) AND A 4'-OXYBIPHENYL-4-CARBONYL UNIT (B) AND 1 TO 400 PARTS BY WEIGHT OF AN INORGANIC FILLER. SUMITOMO CEMICAL COMPANY, LIMITED (JP) 2001-01-23 US claimed
JP-11029699-A None JP disclosed
US-20250170283-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2025-05-29 US disclosed
WO-2024226603-A1 THERAPEUTIC COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2024-10-31 WO disclosed
US-20240100199-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2024-03-28 US disclosed
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2023-09-05 US disclosed
CN-107619432-B Glycopeptide derivative and pharmaceutically acceptable salt, preparation method and application thereof 上海来益生物药物研究开发中心有限责任公司 2023-03-17 CN disclosed
WO-1998055473-A1 POLYMERISABLE, OPTICALLY ACTIVE DIOXOLANE DIESTERS ROLIC AG (CH) 1998-12-10 WO disclosed
WO-1994018229-A1 1,2,4-TRIAZINONE DERIVATIVES AND THEIR USE IN THERAPY FISONS CORPORATION (US) 1994-08-18 WO disclosed
US-4950809-A REACTING ARYL KETONE OR ALDEHYDE WITH PERACETIC ACID RHONE-POULENC CHIMIE (FR) 1990-08-21 US disclosed
US-4613619-A Anti-arrhythmic amino-alcohols AKZO N.V. (NL) 1986-09-23 US disclosed
EP-0155721-A1 Novel anti-arrhythmic amino-alcohols AKZO N.V. (NL) 1985-09-25 EP disclosed
US-4071681-A Process for preparing beta-lactam antibiotic substances SANKYO COMPANY LIMITED (JA) 1978-01-31 US disclosed
US-4016155-A Process for preparing cephalosporin derivatives SANKYO COMPANY LIMITED (JA) 1977-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250170283-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 ALDH5A1 2948/4885ABAT 2794/4885ESR1 3904/4885
US-20020035104-A1 Integrin receptor inhibitors ITGB1, ITGA1, ITGA4 ALDH5A1 4683/4885ABAT 4802/4885ESR1 1516/4885
US-20240100199-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 ALDH5A1 2948/4885ABAT 2794/4885ESR1 3904/4885
US-20050187284-A1 Integrin receptor inhibitors ITGA4, ITGB4, ITGB1 ALDH5A1 4753/4885ABAT 4738/4885ESR1 1137/4885
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents FABP3, TNNI3, TNNT2 ALDH5A1 2948/4885ABAT 2794/4885ESR1 3904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.